Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Polihexanide + propamidine** is a combination of two small molecule antiseptics used topically in ophthalmology, primarily for the treatment of **Acanthamoeba keratitis**, a rare, sight-threatening corneal infection. Polihexanide (also called polyhexamethyl biguanide, PHMB) is a biguanide antiseptic that disrupts cytoplasmic membranes and damages genetic material of Acanthamoeba, leading to cell death. Propamidine is an aromatic diamidine compound that acts as an anti-amoebic and antibacterial agent by interfering with DNA function. This combination is not a licensed product but is widely used in clinical practice, typically prepared as PHMB 0.02% and propamidine 0.1% eye drops, and administered hourly initially, then tapered. Clinical studies have demonstrated its safety and efficacy, with favorable visual outcomes and a reduced need for corneal transplantation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polihexanide + propamidine.